Cargando…

Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs

Seventeen dogs were treated with L-ornithin-L-aspartate (LOLA; experimental group). Three dogs were treated with lactulose recognized therapy (control group). Following LOLA administration, 15 dogs experienced a significant decrease in ammonia level (p < 0.05) and showed clinical signs of improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Jin-Ok, Li, Qiang, Lee, Young-Heun, Han, Sei-Myoung, Hwang, Cheol-Yong, Youn, Hwa-Young, Chung, Jin-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Veterinary Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037314/
https://www.ncbi.nlm.nih.gov/pubmed/26726023
http://dx.doi.org/10.4142/jvs.2016.17.3.431
Descripción
Sumario:Seventeen dogs were treated with L-ornithin-L-aspartate (LOLA; experimental group). Three dogs were treated with lactulose recognized therapy (control group). Following LOLA administration, 15 dogs experienced a significant decrease in ammonia level (p < 0.05) and showed clinical signs of improvement. However, there were no clinical signs of improvement in two dogs, even though the ammonia level decreased. Conversely, the clinical signs of the control group also improved and the ammonia level decreased, although these changes were not significant (p > 0.05). These results suggest that LOLA is an effective drug to treat hyperammonemia in veterinary medicine.